Found: 8
Select item for more details and to access through your institution.
Methodology for Smooth Transition from Experience-Based to Data-Driven Credit Risk Assessment Modeling under Data Scarcity.
- Published in:
- Mathematics (2227-7390), 2024, v. 12, n. 15, p. 2410, doi. 10.3390/math12152410
- By:
- Publication type:
- Article
PLA2G12A protects against diet‐induced obesity and insulin resistance by enhancing energy expenditure and clearance of circulating triglycerides.
- Published in:
- FASEB Journal, 2024, v. 38, n. 9, p. 1, doi. 10.1096/fj.202302075R
- By:
- Publication type:
- Article
Seroprevalence of neutralizing antibodies against adenovirus type 26 and 35 in healthy populations from Guangdong and Shandong provinces, China.
- Published in:
- Virologica Sinica (16740769), 2023, v. 38, n. 2, p. 716, doi. 10.1016/j.virs.2022.06.006
- By:
- Publication type:
- Article
Seroprevalence of neutralizing antibodies against adenovirus type 26 and 35 in healthy populations from Guangdong and Shandong provinces, China.
- Published in:
- Virologica Sinica (16740769), 2022, v. 37, n. 5, p. 716, doi. 10.1016/j.virs.2022.06.006
- By:
- Publication type:
- Article
Intranasal adenovirus-vectored Omicron vaccine induced nasal immunoglobulin A has superior neutralizing potency than serum antibodies.
- Published in:
- Signal Transduction & Targeted Therapy, 2024, v. 9, n. 1, p. 1, doi. 10.1038/s41392-024-01906-0
- By:
- Publication type:
- Article
Intranasal adenovirus-vectored Omicron vaccine induced nasal immunoglobulin A has superior neutralizing potency than serum antibodies.
- Published in:
- Signal Transduction & Targeted Therapy, 2024, v. 9, n. 1, p. 1, doi. 10.1038/s41392-024-01906-0
- By:
- Publication type:
- Article
Correction To: Intranasal booster using an Omicron vaccine confers broad mucosal and systemic immunity against SARS-CoV-2 variants.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Intranasal booster using an Omicron vaccine confers broad mucosal and systemic immunity against SARS-CoV-2 variants.
- Published in:
- Signal Transduction & Targeted Therapy, 2023, v. 8, n. 1, p. 1, doi. 10.1038/s41392-023-01423-6
- By:
- Publication type:
- Article